Valuation: Basilea Pharmaceutica AG

Market Cap 81Cr 101.85Cr 87Cr 75Cr 140.29Cr 9.75TCr 143.05Cr 965.24Cr 376.27Cr 4.88TCr 382.43Cr 374.11Cr 16TCr P/E 2026 *
19.3x
P/E 2027 * 19.8x
Enterprise Value 66Cr 83Cr 71Cr 61Cr 114.41Cr 7.95TCr 116.66Cr 787.2Cr 306.87Cr 3.98TCr 311.89Cr 305.11Cr 13TCr EV / Sales 2026 *
2.55x
EV / Sales 2027 * 2.22x
Free-Float
91.73%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 61 19/04/2018
Director of Finance/CFO 52 10/04/2019
Chief Tech/Sci/R&D Officer 62 01/05/2018
Director TitleAgeSince
Director/Board Member 70 29/11/2011
Chairman 71 09/04/2013
Director/Board Member 73 27/04/2017
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00% - - 101.85Cr
-0.09%+3.87%+3.07%+24.37% 5.12TCr
-1.36%+4.82%+485.55%+614.84% 4.54TCr
-2.04%+3.69%+19.34%+91.23% 4.2TCr
+2.72%+6.02%+33.33%+19.66% 4.21TCr
0.00%-3.91%+18.49%+47.98% 3.19TCr
-1.85%+3.48% - - 1.67TCr
+0.72%+5.27%+31.55%+145.37% 1.71TCr
-0.80%+2.56%+6.24%+34.38% 1.48TCr
+0.50%+3.62%+82.64%+46.53% 1.39TCr
Average -0.22%+3.24%+85.03%+128.04% 3.06TCr
Weighted average by Cap. -0.22%+3.18%+103.62%+150.83%

Financials

2026 *2027 *
Net sales 26Cr 33Cr 28Cr 24Cr 45Cr 3.12TCr 46Cr 309.21Cr 120.54Cr 1.56TCr 122.51Cr 119.84Cr 5.18TCr 27Cr 34Cr 29Cr 25Cr 47Cr 3.24TCr 48Cr 320.92Cr 125.1Cr 1.62TCr 127.15Cr 124.38Cr 5.38TCr
Net income 5.36Cr 6.7Cr 5.74Cr 4.91Cr 9.23Cr 641.5Cr 9.42Cr 64Cr 25Cr 321.49Cr 25Cr 25Cr 1.06TCr 4.44Cr 5.56Cr 4.76Cr 4.08Cr 7.66Cr 532.18Cr 7.81Cr 53Cr 21Cr 266.71Cr 21Cr 20Cr 882.97Cr
Net Debt -15Cr -19Cr -16Cr -14Cr -26Cr -1.8TCr -26Cr -178.04Cr -69Cr -900.86Cr -71Cr -69Cr -2.98TCr -21Cr -27Cr -23Cr -20Cr -37Cr -2.56TCr -38Cr -253.5Cr -99Cr -1.28TCr -100.44Cr -98Cr -4.25TCr
Logo Basilea Pharmaceutica AG
Basilea Pharmaceutica AG Allschwil, formerly known as Basilea Pharmaceutica AG, is a Switzerland-based commercial-stage biopharmaceutical company. The Company operates in one segment, which is the discovery, development, and commercialization of pharmaceutical products to meet the needs of patients with severe bacterial and fungal infections. It launched two hospital brands, Cresemba, which is an intravenous and oral drug for the treatment of invasive fungal infections, and Zevtera, which is an intravenous antibiotic for the treatment of severe bacterial infections, especially pneumonia. Additionally, the Company has several preclinical anti-infective assets in their portfolio. Company's products are present in United States, Canada, Europe, Asia, and Africa.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
BB